Abstract
Computer-aided pattern analysis (C@PA) was recently presented as a powerful tool to predict multitarget ABC transporter inhibitors. The backbone of this computational methodology was the statistical analysis of frequently occurring molecular features amongst a fixed set of reported small-molecules that had been evaluated toward ABCB1, ABCC1, and ABCG2. As a result, negative and positive patterns were elucidated, and secondary positive substructures could be suggested that complemented the multitarget fingerprints. Elevating C@PA to a non-statistical and exploratory level, the concluded secondary positive patterns were extended with potential positive substructures to improve C@PA's prediction capabilities and to explore its robustness. A small-set compound library of known ABCC1 inhibitors with a known hit rate for triple ABCB1, ABCC1, and ABCG2 inhibition was taken to virtually screen for the extended positive patterns. In total, 846 potential broad-spectrum ABCB1, ABCC1, and ABCG2 inhibitors resulted, from which 10 have been purchased and biologically evaluated. Our approach revealed 4 novel multitarget ABCB1, ABCC1, and ABCG2 inhibitors with a biological hit rate of 40%, but with a slightly lower inhibitory power than derived from the original C@PA. This is the very first report about discovering novel broad-spectrum inhibitors against the most prominent ABC transporters by improving C@PA.
| Original language | English |
|---|---|
| Journal | Computational and structural biotechnology journal |
| Volume | 19 |
| Pages (from-to) | 3269-3283 |
| Number of pages | 15 |
| ISSN | 2001-0370 |
| DOIs | |
| Publication status | Published - 01.2021 |
Funding
VN thanks ChemAxon for providing an academic research license to their software. JP received funding from Deutsche Forschungsgemeinschaft (DFG; German Research Foundation)/ Germany (DFG 263024513); EFRE und Ministerium f?r Wirtschaft, Wissenschaft und Digitalisierung achsen-Anhalt/ Germany (ZS/2016/05/78617); Latvian Council of Science/ Latvia (lzp-2018/1-0275); Nasjonalforeningen (16154), HelseS?/ Norway (2016062, 2019054, 2019055); Barnekreftforeningen (19008); EEA grant/Norway grants Kappa programme (TA?R TARIMAD TO100078); Norges forskningsr?det/ Norway (251290, 260786 PROP-AD, 295910 NAPI, and 327571 PETABC); European Commission (643417). PROP-AD and PETABC are EU Joint Programme - Neurodegenerative Disease Research (JPND) projects. PROP-AD is supported through the following funding organizations under the aegis of JPND - www.jpnd.eu (AKA #301228 ? Finland, BMBF #01ED1605 ? Germany, CSO-MOH #30000-12631 ? Israel, NFR #260786 ? Norway, SRC #2015-06795 ? Sweden). PETABC is supported through the following funding organisations under the aegis of JPND - www.jpnd.eu (NFR #327571 ? Norway, FFG #882717 ? Austria, BMBF ? Germany, MSMT #8F21002? Czech Republic, VIAA #ES RTD/2020/26 ? Latvia, ANR #20-JPW2-0002-04 - France, SRC #2020-02905 ? Sweden). The projects receive funding from the European Union's Horizon 2020 research and innovation programme under grant agreement #643417 (JPco-fuND). SMS receives a Walter Benjamin fellowship of the DFG; 446812474). VN thanks ChemAxon for providing an academic research license to their software. JP received funding from Deutsche Forschungsgemeinschaft (DFG; German Research Foundation)/ Germany (DFG 263024513); EFRE und Ministerium für Wirtschaft, Wissenschaft und Digitalisierung achsen-Anhalt/ Germany (ZS/2016/05/78617); Latvian Council of Science/ Latvia (lzp-2018/1-0275); Nasjonalforeningen (16154), HelseSØ/ Norway (2016062, 2019054, 2019055); Barnekreftforeningen (19008); EEA grant/Norway grants Kappa programme (TAČR TARIMAD TO100078); Norges forskningsrådet/ Norway (251290, 260786 PROP-AD, 295910 NAPI, and 327571 PETABC); European Commission (643417). PROP-AD and PETABC are EU Joint Programme - Neurodegenerative Disease Research (JPND) projects. PROP-AD is supported through the following funding organizations under the aegis of JPND - www.jpnd.eu (AKA #301228 – Finland, BMBF #01ED1605 – Germany, CSO-MOH #30000-12631 – Israel, NFR #260786 – Norway, SRC #2015-06795 – Sweden). PETABC is supported through the following funding organisations under the aegis of JPND - www.jpnd.eu (NFR #327571 – Norway, FFG #882717 – Austria, BMBF – Germany, MSMT #8F21002– Czech Republic, VIAA #ES RTD/2020/26 – Latvia, ANR #20-JPW2-0002-04 - France, SRC #2020-02905 – Sweden). The projects receive funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement #643417 (JPco-fuND). SMS receives a Walter Benjamin fellowship of the DFG; 446812474).
Research Areas and Centers
- Academic Focus: Center for Infection and Inflammation Research (ZIEL)